Multiple randomized controlled trials (RCTs) have demonstrated the potential benefits of GLP-1RAs, DPP-4 inhibitors, and SGLT-2 inhibitors for treating NAFLD in diabetic patients. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.